What does the evidence say about Silymarin Metabolic Health Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Silymarin Metabolic Health Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Conclusion Silymarin combined with lifestyle modifications is a safe and effective treatment option for reducing and normalizing liver enzyme levels in patients with NAFLD and associated metabolic syndrome. [Sukeepaisarnjaroen W (2026); evidence level 4] - Background Non-alcoholic fatty liver disease (NAFLD) has now become a major global health concern. [Sukeepaisarnjaroen W (2026); evidence level 4] - Lifestyle modifications are the first line of treatment; however, their effectiveness is often limited. [Sukeepaisarnjaroen W (2026); evidence level 4] - Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing global health concern with limited effective therapies. [Tawfik MF (2025); evidence level 4] - The phytocomplex formulation significantly reduced serum ALT, AST, ALP, and GGT, improved lipid profiles, and restored hepatic architecture, with MASLD-AS and PPAR-α expression demonstrating a marked reduction in hepatic injury and oxidative stress. [Tawfik MF (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.